https://stock.noler.com/us/stock/vansen-pharma-inc https://stock.noler.com/us/stock/vansen-pharma-inc/accounts-payable https://stock.noler.com/us/stock/vansen-pharma-inc/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/vansen-pharma-inc/accounts-payable-and-accrued-liabilities-current-and-noncurrent https://stock.noler.com/us/stock/vansen-pharma-inc/accounts-payable-and-other-accrued-liabilities https://stock.noler.com/us/stock/vansen-pharma-inc/accounts-payable-trade-current-and-noncurrent https://stock.noler.com/us/stock/vansen-pharma-inc/accounts-receivable https://stock.noler.com/us/stock/vansen-pharma-inc/accretion-expense https://stock.noler.com/us/stock/vansen-pharma-inc/acquisition-separately-recognized-transactions-additional-disclosures-acquisition-costs https://stock.noler.com/us/stock/vansen-pharma-inc/additional-paid-in-capital https://stock.noler.com/us/stock/vansen-pharma-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/vansen-pharma-inc/allowance-for-credit-losses-change-in-method-of-calculating-impairment https://stock.noler.com/us/stock/vansen-pharma-inc/amortization https://stock.noler.com/us/stock/vansen-pharma-inc/aoci https://stock.noler.com/us/stock/vansen-pharma-inc/asset-impairment-charges https://stock.noler.com/us/stock/vansen-pharma-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/vansen-pharma-inc/business-acquisition-cost-of-acquired-entity-transaction-costs https://stock.noler.com/us/stock/vansen-pharma-inc/cash https://stock.noler.com/us/stock/vansen-pharma-inc/cash-and-equivalents https://stock.noler.com/us/stock/vansen-pharma-inc/cash-change https://stock.noler.com/us/stock/vansen-pharma-inc/cash-flow-breakdown https://stock.noler.com/us/stock/vansen-pharma-inc/cash-provided-by-used-in-financing-activities-discontinued-operations https://stock.noler.com/us/stock/vansen-pharma-inc/cash-provided-by-used-in-operating-activities-discontinued-operations https://stock.noler.com/us/stock/vansen-pharma-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/vansen-pharma-inc/common-stock-value https://stock.noler.com/us/stock/vansen-pharma-inc/comprehensive-income https://stock.noler.com/us/stock/vansen-pharma-inc/convertible-notes-payable https://stock.noler.com/us/stock/vansen-pharma-inc/convertible-notes-payable-current https://stock.noler.com/us/stock/vansen-pharma-inc/cost-of-goods-sold https://stock.noler.com/us/stock/vansen-pharma-inc/costs-and-expenses https://stock.noler.com/us/stock/vansen-pharma-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/vansen-pharma-inc/current-assets https://stock.noler.com/us/stock/vansen-pharma-inc/current-liabilities https://stock.noler.com/us/stock/vansen-pharma-inc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/vansen-pharma-inc/debt-unamortized-discount-premium-net https://stock.noler.com/us/stock/vansen-pharma-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/vansen-pharma-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/vansen-pharma-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/vansen-pharma-inc/derivative-fair-value-of-derivative-liability https://stock.noler.com/us/stock/vansen-pharma-inc/derivative-liabilities-current https://stock.noler.com/us/stock/vansen-pharma-inc/development-stage-enterprise-deficit-accumulated-during-development-stage https://stock.noler.com/us/stock/vansen-pharma-inc/dilutive-shares https://stock.noler.com/us/stock/vansen-pharma-inc/direct-taxes-and-licenses-costs https://stock.noler.com/us/stock/vansen-pharma-inc/disposal-group-including-discontinued-operation-accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/vansen-pharma-inc/due-to-officers-or-stockholders-current-and-noncurrent https://stock.noler.com/us/stock/vansen-pharma-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/vansen-pharma-inc/equity-issuance-per-share-amount https://stock.noler.com/us/stock/vansen-pharma-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/vansen-pharma-inc/fair-value-assumptions-expected-dividend-payments https://stock.noler.com/us/stock/vansen-pharma-inc/fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/vansen-pharma-inc/fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/vansen-pharma-inc/fair-value-net-derivative-asset-liability-unobservable-inputs-reconciliation-gain-loss-included-in-earnings https://stock.noler.com/us/stock/vansen-pharma-inc/financing-cash-flow https://stock.noler.com/us/stock/vansen-pharma-inc/general-and-administrative-expense https://stock.noler.com/us/stock/vansen-pharma-inc/goodwill-and-intangible-asset-impairment https://stock.noler.com/us/stock/vansen-pharma-inc/goodwill-impairment-loss https://stock.noler.com/us/stock/vansen-pharma-inc/gross-profit https://stock.noler.com/us/stock/vansen-pharma-inc/income-loss-from https://stock.noler.com/us/stock/vansen-pharma-inc/income-loss-from-discontinued-operations-net-of-tax https://stock.noler.com/us/stock/vansen-pharma-inc/income-loss-from-per-basic-and-diluted-share https://stock.noler.com/us/stock/vansen-pharma-inc/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/vansen-pharma-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/vansen-pharma-inc/increase-decrease-in-accrued-interest-receivable-net https://stock.noler.com/us/stock/vansen-pharma-inc/increase-decrease-in-due-to-related-parties https://stock.noler.com/us/stock/vansen-pharma-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/vansen-pharma-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/vansen-pharma-inc/increase-decrease-in-prepaid-expense https://stock.noler.com/us/stock/vansen-pharma-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/vansen-pharma-inc/interest-expense https://stock.noler.com/us/stock/vansen-pharma-inc/interest-expense-related-party https://stock.noler.com/us/stock/vansen-pharma-inc/interest-paid https://stock.noler.com/us/stock/vansen-pharma-inc/inventory https://stock.noler.com/us/stock/vansen-pharma-inc/inventory-finished-goods https://stock.noler.com/us/stock/vansen-pharma-inc/inventory-raw-materials https://stock.noler.com/us/stock/vansen-pharma-inc/investing-cash-flow https://stock.noler.com/us/stock/vansen-pharma-inc/liabilities-of-disposal-group-including-discontinued-operation-current https://stock.noler.com/us/stock/vansen-pharma-inc/long-term-debt https://stock.noler.com/us/stock/vansen-pharma-inc/net-cash-from-discontinued-operations https://stock.noler.com/us/stock/vansen-pharma-inc/net-change-in-cash https://stock.noler.com/us/stock/vansen-pharma-inc/net-income https://stock.noler.com/us/stock/vansen-pharma-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/vansen-pharma-inc/noncash-or-part-noncash-acquisition-intangible-assets-acquired https://stock.noler.com/us/stock/vansen-pharma-inc/notes-and-loans-payable-current https://stock.noler.com/us/stock/vansen-pharma-inc/notes-and-loans-receivable-gross-current https://stock.noler.com/us/stock/vansen-pharma-inc/notes-payable https://stock.noler.com/us/stock/vansen-pharma-inc/notes-payable-current https://stock.noler.com/us/stock/vansen-pharma-inc/notes-payable-related-parties-classified-current https://stock.noler.com/us/stock/vansen-pharma-inc/oci-foreign-currency-transaction-and-translation-adjustment-before-tax https://stock.noler.com/us/stock/vansen-pharma-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/vansen-pharma-inc/operating-cash-flow https://stock.noler.com/us/stock/vansen-pharma-inc/operating-expenses https://stock.noler.com/us/stock/vansen-pharma-inc/operating-income https://stock.noler.com/us/stock/vansen-pharma-inc/other-income https://stock.noler.com/us/stock/vansen-pharma-inc/other-intangible-assets-net https://stock.noler.com/us/stock/vansen-pharma-inc/other-nonoperating-income https://stock.noler.com/us/stock/vansen-pharma-inc/other-selling-and-marketing-expense https://stock.noler.com/us/stock/vansen-pharma-inc/payments-to-acquire-other-productive-assets https://stock.noler.com/us/stock/vansen-pharma-inc/prepaid-expense-current https://stock.noler.com/us/stock/vansen-pharma-inc/proceeds-from-convertible-debt https://stock.noler.com/us/stock/vansen-pharma-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/vansen-pharma-inc/proceeds-from-related-party-debt https://stock.noler.com/us/stock/vansen-pharma-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/vansen-pharma-inc/professional-fees https://stock.noler.com/us/stock/vansen-pharma-inc/public-float https://stock.noler.com/us/stock/vansen-pharma-inc/related-party-transaction-rate https://stock.noler.com/us/stock/vansen-pharma-inc/retained-earnings https://stock.noler.com/us/stock/vansen-pharma-inc/revenue https://stock.noler.com/us/stock/vansen-pharma-inc/salaries-wages-and-officers-compensation https://stock.noler.com/us/stock/vansen-pharma-inc/shareholders-equity https://stock.noler.com/us/stock/vansen-pharma-inc/shares-authorized https://stock.noler.com/us/stock/vansen-pharma-inc/shares-issued https://stock.noler.com/us/stock/vansen-pharma-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/vansen-pharma-inc/stock-issued-shares-issued-shares-issued-for-cash https://stock.noler.com/us/stock/vansen-pharma-inc/stock-issued-shares-issued-value-issued-for-cash https://stock.noler.com/us/stock/vansen-pharma-inc/total-assets https://stock.noler.com/us/stock/vansen-pharma-inc/total-liabilities https://stock.noler.com/us/stock/vansen-pharma-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/vansen-pharma-inc/weighted-average-number-of-share-outstanding-basic-and-diluted